uniQure (NASDAQ:QURE) Shares Gap Up – Here’s What Happened

Shares of uniQure N.V. (NASDAQ:QURE) gapped up before the market opened on Thursday. The stock had previously closed at $20.97, but opened at $21.94. uniQure shares last traded at $21.8710, with a volume of 256,843 shares.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on QURE. Mizuho lifted their target price on shares of uniQure from $35.00 to $68.00 and gave the stock an “outperform” rating in a research note on Thursday, June 25th. Wolfe Research upgraded shares of uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 price target on the stock in a research note on Wednesday, July 29th. Wall Street Zen cut shares of uniQure from a “hold” rating to a “sell” rating in a research note on Saturday, September 5th. UBS Group reaffirmed a “buy” rating and issued a $48.00 price objective (up from $27.00) on shares of uniQure in a report on Thursday. Finally, William Blair upgraded shares of uniQure to a “strong-buy” rating in a research note on Wednesday, September 23rd. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, uniQure presently has an average rating of “Moderate Buy” and a consensus target price of $53.25.

uniQure Stock Performance

The company has a debt-to-equity ratio of 0.15, a current ratio of 10.01 and a quick ratio of 10.01. The company has a 50 day simple moving average of $39.26 and a 200-day simple moving average of $33.80. The firm has a market cap of $1.51 billion, a PE ratio of -5.43 and a beta of 1.06.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.40). uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%. The company had revenue of $5.84 million for the quarter, compared to the consensus estimate of $5.45 million. During the same quarter in the previous year, the business earned ($0.69) earnings per share. As a group, equities research analysts anticipate that uniQure N.V. will post -3.82 EPS for the current year.

Hedge Funds Weigh In On uniQure

Large investors have recently made changes to their positions in the business. Avoro Capital Advisors LLC lifted its position in uniQure by 38.4% in the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock valued at $147,170,000 after acquiring an additional 1,705,556 shares in the last quarter. Orbimed Advisors LLC boosted its stake in uniQure by 189.7% during the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock valued at $34,926,000 after purchasing an additional 1,398,749 shares during the last quarter. Two Seas Capital LP bought a new stake in shares of uniQure in the 3rd quarter worth $31,988,000. Assenagon Asset Management S.A. increased its holdings in shares of uniQure by 249.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 513,530 shares of the biotechnology company’s stock worth $23,653,000 after purchasing an additional 366,781 shares in the last quarter. Finally, Siren L.L.C. bought a new stake in shares of uniQure in the 1st quarter worth $16,350,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on developing gene therapies intended to treat serious and potentially life-threatening diseases. The company uses adeno-associated virus (AAV) delivery technology to introduce genetic material into patients’ cells, with the goal of addressing the underlying causes of disease through a single administration.

uniQure’s lead commercial product, Hemgenix (etranacogene dezaparvovec), is a gene therapy for adults with hemophilia B who use factor IX replacement therapy.